Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Gilead Sciences, in collaboration with Eisai Korea Inc., is conducting a Phase 4 clinical study titled A Multi-center, Open-Label, Single-Arm, Phase 4 Study to Evaluate the Efficacy and Safety of Filgotinib 200 mg in Korean Patients With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice. The study aims to assess the efficacy of filgotinib in achieving clinical remission in patients with ulcerative colitis, highlighting its potential significance in routine clinical settings.
Intervention/Treatment: The study tests Filgotinib Maleate, an oral drug administered at 200 mg per day, aimed at treating moderately to severely active ulcerative colitis.
Study Design: This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. Participants receive the experimental drug, Filgotinib Maleate, to evaluate its effectiveness and safety.
Study Timeline: The study began on June 11, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
Market Implications: The ongoing study could influence Gilead Sciences’ stock performance positively if results demonstrate significant efficacy and safety, enhancing investor confidence. As the pharmaceutical industry closely watches advancements in ulcerative colitis treatments, successful outcomes could position Gilead favorably against competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.